Isolicoflavonol

Isolicoflavonol inhibits Human carboxylesterase 2 (hCES2A) which is a key target to ameliorate the intestinal toxicity triggered by irinotecan that causes severe diarrhea in 50%-80% of patients receiving this anticancer agent.